Genzyme sees revenue rise

Genzyme, the subject of an $18.5bn hostile takeover bid from Sanofi-Aventis, yesterday forecast a rise in fourth-quarter revenue. It expects fourth-quarter revenue to rise 23 per cent to $1.154bn. Analysts expect fourth-quarter revenue of $1.19bn.